Search
Rhythm Pharmaceuticals Inc
RYTMAdd to Watchlist
96.790USD
+0.960+1.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
6.45BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Rhythm Pharmaceuticals Inc is 8.63, ranking 24 out of 157 in the Pharmaceuticals industry. The average price target is 127.00, with a high of 141.00 and a low of 110.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
139.467
Target Price
+44.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Rhythm Pharmaceuticals Inc
RYTM
16
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Rhythm Pharmaceuticals Inc's expected revenue for the next quarter?
Rhythm Pharmaceuticals Inc's expected revenue is 67.46M.
What is Rhythm Pharmaceuticals Inc's price target?
Analysts forecast that Rhythm Pharmaceuticals Inc's price target is USD 127.00, with the highest forecast at USD 141.00 and the lowest forecast at USD 110.00.
How have Rhythm Pharmaceuticals IncRYTM's recent earnings per share performed?
The market expectation was USD -0.83, while Rhythm Pharmaceuticals IncRYTM's earnings per share (EPS) for the previous quarter was USD -0.73. EPS for the next quarter is expected at USD -0.83.
What is the analyst rating for Rhythm Pharmaceuticals Inc?
Based on the ratings of Rhythm Pharmaceuticals Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
